AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in its immunology and neuroscience portfolios, supporting continued optimism. The company's ability to exceed expectations amid headwinds underscores management's effective execution and portfolio diversification. Maintaining a bullish stance, I see ABBV's recent results as reinforcing its long-term investment thesis and outlook. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » kynny/iStock via Getty Images The last time I spoke about AbbVie Inc. ( ABBV ) it was in a Seeking Alpha article entitled as " AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating ." For More on my IG service This article is published by Terry Chrisomalis, who runs the data-mce-href="https://seekingalpha.com/account/research/login_and_subscribe?slug=terry-chrisomalis" Biotech Analysis Central pharm
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (NYSE:ABBV) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- AbbVie (NYSE:ABBV) was given a new $230.00 price target on by analysts at UBS Group AG.MarketBeat
- AbbVie: The Market Is Getting It Wrong [Seeking Alpha]Seeking Alpha
- AbbVie (NYSE:ABBV) had its price target raised by analysts at Morgan Stanley from $269.00 to $270.00. They now have an "overweight" rating on the stock.MarketBeat
- AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 2/4/26 - Form 8-K
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- ABBV's page on the SEC website